Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells by Dago,  A. E. et al.
Rapid Phenotypic and Genomic Change in Response to
Therapeutic Pressure in Prostate Cancer Inferred by High
Content Analysis of Single Circulating Tumor Cells
Angel E. Dago1., Asya Stepansky2,3., Anders Carlsson1, Madelyn Luttgen1, Jude Kendall2,3,
Timour Baslan2,4, Anand Kolatkar1, Michael Wigler2, Kelly Bethel1,5, Mitchell E. Gross6, James Hicks2*,
Peter Kuhn7*
1Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California, United States of America, 2Cold Spring Harbor Laboratory, Cold Spring
Harbor, New York, United States of America, 3 Skyline Genomics, Roslyn Heights, New York, United States of America, 4Department of Molecular and Cellular Biology,
Stony Brook University, Stony Brook, New York, United States of America, 5Department of Pathology, Scripps Clinic, La Jolla, California, United States of America, 6 Keck
School of Medicine, University of Southern California, Los Angeles, California, United States of America, 7Dornsife College of Letters, Arts and Sciences, University of
Southern California, Los Angeles, California, United States of America
Abstract
Timely characterization of a cancer’s evolution is required to predict treatment efficacy and to detect resistance early. High
content analysis of single Circulating Tumor Cells (CTCs) enables sequential characterization of genotypic, morphometric
and protein expression alterations in real time over the course of cancer treatment. This concept was investigated in a
patient with castrate-resistant prostate cancer progressing through both chemotherapy and targeted therapy. In this case
study, we integrate across four timepoints 41 genome-wide copy number variation (CNV) profiles plus morphometric
parameters and androgen receptor (AR) protein levels. Remarkably, little change was observed in response to standard
chemotherapy, evidenced by the fact that a unique clone (A), exhibiting highly rearranged CNV profiles and AR+ phenotype
was found circulating before and after treatment. However, clinical response and subsequent progression after targeted
therapy was associated with the drastic depletion of clone A, followed by the sequential emergence of two distinct CTC sub-
populations that differed in both AR genotype and expression phenotype. While AR- cells with flat or pseudo-diploid CNV
profiles (clone B) were identified at the time of response, a new tumor lineage of AR+ cells (clone C) with CNV altered
profiles was detected during relapse. We showed that clone C, despite phylogenetically related to clone A, possessed a
unique set of somatic CNV alterations, including MYC amplification, an event linked to hormone escape. Interesting, we
showed that both clones acquired AR gene amplification by deploying different evolutionary paths. Overall, these data
demonstrate the timeframe of tumor evolution in response to therapy and provide a framework for the multi-scale analysis
of fluid biopsies to quantify and monitor disease evolution in individual patients.
Citation: Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, et al. (2014) Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in
Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells. PLoS ONE 9(8): e101777. doi:10.1371/journal.pone.0101777
Editor: Surinder K. Batra, University of Nebraska Medical Center, United States of America
Received December 13, 2013; Accepted June 11, 2014; Published August 1, 2014
Copyright:  2014 Dago et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Award Number U54CA143906 from the National Cancer Institute. A. E. Dago is a recipient of a PA-12-149- Research
Supplements to Promote Diversity in Health-Related Research awarded by the National Cancer Institute (NCI). A. Carlsson is funded by the Swedish Research
Council, Dnr 2012–235. JH, JK, TB and MW were supported by a special grant from Dr. Marilyn Simons for cancer research at CSHL, a Breast Cancer Research
Foundation grant, and research support from Skyline Genomics. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript. Dr. Asya Stepansky of Skyline Genomics had a significant role in developing the protocol for isolating DNA from HD-CTC cells and
performed the Illumina library preparations. Skyline Genomics financially supported the Illumina sequencing at the Cold Spring Harbor Genome facility as a
demonstration of their capabilities as a future service provider. The company did not have a role in design of the experiments or interpretation of the data.
Competing Interests: The authors have read the journal’s policy and have conflicts to disclose. The HD-CTC assay technology described here has been licensed
to Epic Sciences. ML, AK, KB and PK have ownership interests in Epic Sciences. AS is an employee of Skyline Genomics, and had a significant role in developing the
protocol for isolating DNA from HD-CTC cells and performed the Illumina library preparations. AS did not have any role in design of the experiments or
interpretation of the data. JH is a co-founder and shareholder in skyline genomics. AED, AC, JK, TB, MW and MEG and have declared that no competing interests
exist.
* Email: pkuhn@usc.edu (PK); hicks@cshl.edu (JH)
. These authors contributed equally to this work.
Introduction
The androgen-androgen receptor (AR) signaling pathway is
essential for the development and progression of prostate cancer
and is a key target of many therapeutic agents [1]. In metastatic
prostate cancer (PCa), androgen deprivation therapy (ADT),
constitutes the gold standard treatment to induce tumor regression
by suppressing AR activation. Despite initial response to ADT,
patients often develop resistance and progress to castration
resistant prostate cancer (CRPC), an incurable disease with poor
prognosis. These patients are often treated with salvage hormone-
directed therapies, including agents such as non-steroidal anti-
androgens and androgen-synthesis inhibitors [1]. In managing
these treatments, predicting therapeutic response and identifying
early indicators of therapy resistance are major challenges. The
levels of prostate specific antigen (PSA), an androgen regulated
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protein measured in the serum, is used to monitor therapeutic
response in CRPC patients, however its predictive capability for
this patient group is limited [2]. In addition, while many studies
have identified molecular events that may contribute to therapeu-
tic resistance to androgen-targeting agents, it is difficult to apply
these findings due to the limited supply of sequentially acquired
tissue and the expected heterogeneity across multiple metastatic
deposits present in any individual patient [3,4]. As such, methods
that would allow for non-invasive sequential monitoring through
the clinical course of therapy would be of tremendous value to
clinicians.
Circulating tumor cells (CTCs) have the potential to provide a
non-invasive means of assessing progressive cancers in real time
during therapy, and further, to help direct therapy by monitoring
phenotypic physiological and genetic changes that occur in
response to therapy. In most CRPC patients, the primary tumor
has been removed, and CTCs are expected to consist of cells shed
from metastases, providing a ‘fluid biopsy’. Currently, the only
method approved for CTC enumeration (CellSearch, Veridex) is
based on an immune enrichment approach that pre-selects for
cells that express Epithelial Cell Adhesion Molecule (EpCAM), an
epithelial cell surface marker [5]. Although, numeric quantifica-
tion of CTCs using CellSearch has yielded some prognostic
information in certain cancers [6–8], this methodology has
limitations such as low sensitivity (cells with low or absent EpCAM
expression won’t be captured) and the regular presence/contam-
ination of genomically normal leukocytes in the sample prepara-
tion that hampers further molecular characterization and data
interpretation. Recently, genomic changes based on array CGH
and limited sequencing has been reported on CTCs isolated with
the CellSearch system [9]. Detailed analysis in paired tumors and
metastasis (n = 2) and CTCs (n = 8) suggested that most mutations
detected in CTCs were present at a low-level in the primary tumor
[9]. However, because a single timepoint during the clinical course
of the disease was investigated this study does not address how a
tumor may respond and evolve to therapeutic pressure.
Here, we demonstrate the power of two newly developed
technologies in order to provide a more comprehensive portrait of
the molecular changes occurring, at the single cell level, in a
CRPC patient under the treatment pressure in both ADT and
chemotherapy settings. The High Definition-CTC (HD-CTC)
method was used for the longitudinal identification and enumer-
ation of CTCs [10] and to asses for the expression of the AR [11].
The assay employs an unbiased protocol to examine and
distinguish CTCs among the surrounding leukocytes based on
their cytokeratin positive (CK+) phenotype by using a high
resolution immunofluorescence imaging. In addition, the HD-
CTC technology preserves the cell morphology in such a way that
enables the morphometric and the indirect quantification of AR
and CK protein expression levels for all the CTCs identified in the
blood sample. To further characterize each CTC, a protocol was
developed for extracting individual cells under conditions suitable
for subsequent genomic analysis by a modification of the single
nucleus sequencing method described by Navin, et al. [12] and
Baslan, et al. [13]. The combined methods enabled to trace over
time the molecular changes in the CTC population by correlating
morphometric and protein expression data with genome wide
CNV alterations for each of 41 individual CTCs isolated at four
clinically significant timepoints. We were able to associate the
emergence of distinct CTC subpopulations endowed with specific
molecular alterations with the clinical course of the disease
especially during the period of targeted ADT, which was clinically
represented by a short period of response followed by resistance
and clinical escape.
Material and Methods
Patient Clinical History and Blood Draws Collected
During Treatment
The study was approved by the institutional review board (IRB)
of University of Southern California Comprehensive Cancer
Center. The patient provided written informed consent.
The patient presented with PCa metastatic to a lumbar
vertebrae at diagnosis for which the primary biopsy represents
the first specimen in this study. Initial treatment consisted of
androgen deprivation therapy (leuprolide acetate). After 5 months,
there was clinical progression to CRPC and the patient was
enrolled in a clinical trial of docetaxel combined with bevacizu-
mab and everolimus (clinicaltrials.gov identifier: NCT00574769).
Before chemotherapy was initiated, a baseline blood draw was
taken (Draw 1) according to the sample collection protocol.
Clinical progression was noted after 4 months of protocol-specified
chemotherapy. Over the next 3 months, additional doses of
docetaxel as well as external-beam radiotherapy and samarium
(153Sm) lexidronam (a bone-targeting radiopharmaceutical) were
employed with limited palliative benefit. At 12 months after
diagnosis, treatment with abiraterone acetate, a highly-selective
androgen synthesis inhibitor, was initiated. Blood was drawn prior
to starting abiraterone (Draw 2), at 3 weeks of continuous
treatment coinciding with a clinical response represented by
decreased pain and PSA level (Draw 3), and at 9 weeks coinciding
with clinical progression represented by increasing pain and PSA
levels (Draw 4). Following abiraterone, treatment was changed to
cabazitaxel without clinical response followed by a rapid clinical
deterioration. The patient died of widely metastatic prostate
cancer 4 months following Draw 4 (17 months after diagnosis).
Blood Sample Collection and Processing for CTC
Detection
Patient peripheral blood samples were collected according to an
IRB approved protocol. Samples were shipped to our laboratory
and processed within 24 hours after the time of draw. Sample
preparation was previously described in [10]. In brief, it consists of
a red blood cell lysis followed by plating of the nucleated cells as a
monolayer on custom made cell-adhesion glass slide followed by
storage in a biorepository. Each sample produced at least 14
independent slides for CTC identification and characterization.
Immunofluorescence Staining and CTC Enumeration
For this study, we used a protocol based on the published HD-
CTC assay coupled with evaluation of androgen receptor (AR)
status within the cytokeratin (CK) positive CTC population [11].
Briefly, the cells were labeled using mouse monoclonal cytokeratin
19 (1:100; Dako) and panCK (1:100; Sigma) primary antibodies to
identify cytokeratin (CK) positive cells. AR positive HD-CTCs
were identified using a rabbit anti-AR monoclonal antibody
(1:250, Cell Signaling Technology). Both the CK and AR antigens
were visualized using AlexaFluor secondary antibodies; the CK
primary antibodies were recognized with Alexa Fluor 555 IgG1
secondary antibody (1:500, Invitrogen) and the rabbit AR
antibody was recognized with Alexa Fluor 488 IgG (H+L)
secondary antibody (1:1000, Invitrogen). Alexa Fluor 647 conju-
gated anti-CD45 (1:125; AbD Serotec) primary antibody was used
to identify leukocytes as an exclusion marker. To confirm that the
cells are nucleated and to enable the analysis of nuclear
morphology all cells were stained with a 4’,6-diamidino-2-
phenylindole (DAPI).
The slides were imaged and putative CTCs were recorded using
a computerized high-throughput fluorescence microscope at 106
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magnification. CTCs were identified by a hematology technician
using the previously published criteria of having a DAPI+ nucleus
plus cytokeratin positivity and CD45 negativity [10]. Androgen
receptor protein expression and localization were evaluated using
two criteria (1) presence (AR+) or absence (AR2) of AR staining,
and (2) AR subcellular localization (nuclear AR versus cytoplasmic
staining or both). The threshold for AR positivity was defined as a
signal more than 6 standard deviations over the mean signal
intensity (SDOM) observed in the surroundings leukocytes
(background). Subcellular localization was measured using the
relative pixel density of AR staining over the nucleus and
cytoplasm.
HD-CTC Assay Reproducibility
The HD-CTC assay was technically validated with cell line
spiking experiments to reach an R2 = 0.9997 on linearity testing as
previously reported. These experiments were performed using SK-
BR-3 cell lines and 0 to 36102 cells per mL of normal donor
control blood. The coefficient of variation is 16% and inter-
processor correlation is R2 = 0.979. Sample preparation process
adhered to standard operating procedures for patient samples
through a bar coded system for all consumables and instrumen-
tation. All off-the-shelf instrumentation was calibrated according
to the technical validation protocols established during the
commissioning [14].
Extraction of Single Cells
As a standard procedure, aimed at minimizing DNA fragmen-
tation cells were picked within 5 days of the initial staining
procedure. The experimental protocol for HD-CTC fluid phase
capture was divided into three discrete sequential steps: (1) CTC
relocation, (2) cell extraction and (3) isolation and manipulation of
single CTCs for downstream molecular analyses.
HD-CTCs were relocated (step 1) using a transformation matrix
from the initial data acquisition for HD-CTC identification. After
calibration and relocation, each candidate cell was re-imaged at
406resolution for the detailed morphometric analysis. For the cell
extraction (step 2) an Eppendorf Transfer Man NK2 microma-
nipulator was used to capture the cell of interest inside a 25u
jagged micropipette (Piezo Drill Tip ES, Eppendorf) by applying
fluid suction. Once the cell of interest was captured inside the
micropipette (step 3), the cell was rinsed with PBS and deposited
inside a 0.2 mL PCR tube containing 2 mL of lysis buffer
(200 mM KOH; 50 mM DTT). The sample was then and
immediately frozen and stored at 280uC until further processing.
All instruments and consumables were decontaminated using a
DNAase solution and exposure to UV light for 30 min prior to the
experiment.
Single Cell Next Generation Sequencing and
Bioinformatic Analysis
The cell containing vials were transferred in dry ice to the
sequencing laboratory. Briefly, the lysed cell mixture was thawed
and subjected to WGA and sequencing library construction as
previously reported [13]. WGA was carried out manually in a 96-
well plate format using the WGA4 Genomeplex Single Cell Whole
Genome Amplification Kit (Sigma-Aldrich), followed by purifica-
tion using a QIAquick 96 PCR Purification Kit (Qiagen).
Concentration of eluted DNA was measured using a Nanodrop
8000 (Thermo Scientific). For each well, amplification was
considered successful if the resulting DNA concentration was $
70 ng/ ml (elution volume of 50 ml), followed by further Quality
Control (QC) to confirm the appropriate sample size distribution
using the Agilent 2100 Bioanalyzer (High-Sensitivity DNA Assay
and Kit, Agilent Technologies).
In addition, detailed methods used to analyze sequencing data
were published recently by our group [13]. Briefly, the informatics
methods involves three steps: first, deconvoluting the sequence
reads based on barcodes; second, mapping the reads to the human
genome (hg19, Genome Reference Consortium GRCh37, UCSC
Genome Browser database) [15], and removing PCR duplicates;
and third, normalizing for guanine-cytosine (GC) content and
estimating copy number using the CBS segmentation algorithm.
The copy number profiles in this report are based on 20,000
variable length genome bins, averaging a length of ,150 kilo-base
pairs each, and were calculated as ratio compared to normal (hg
19). The data reported here had a median count of 1.78 million
uniquely mapping reads, with a range from 244,190 (minimum
cutoff 200,000) to 5.33 million.
Cluster Analysis
The hierarchical clustering was performed in R [16] using the
heatmap.2 function in the gplots package. Ward’s method with
Euclidean distance metric was used for the clustering. The
heatmap is colored according to the cutoffs described above and
the clustering was performed using median centered data.
Frequency Analysis to Define Genomic Alterations
Using median centered CNV profiles, cutoff ratios versus the
median of 0.8 and 1.25 were used to define deletions and
amplifications, respectively. These cutoffs were used both to color
the heatmap and to do the frequency analysis.
Statistics and Cell Morphology Analysis
The cell shape (cell roundness) was analyzed by tracing the cell
cytoplasm contour in the composite image of each CTC. The
traced cell image was imported into R, and an ellipsis was fitted to
the shape using a least squares fitting algorithm described by Halir
and Flusser [17]. The algorithm outputs the cell’s major axis,
which is the largest radius of the fitted ellipsis (Refer to supporting
information). The cell roundness (c) is estimated as the fraction of
the de facto cell area (A) and the area of a circle with the radius (r)




The p-value used in the comparison of the roundness between
the CTCs in Draw 3 and 4 was calculated using the Wilcoxon
sum-rank test.
Results and Discussion
Treatment Response Monitored by Longitudinal CTC
Molecular Analysis
In order to assess the patient’s response to treatment high
content single cell analysis including: (1) AR protein expression
phenotype, (2) AR subcellular localization and (3) CNV genomic
profiling were performed in the CTCs identified in the blood
samples collected across four different intervals representing
decision points in the standard care of CRPC including: (Draw
1) immediately prior to initiation of docetaxel based chemother-
apy, (Draw 2) immediately prior to abiraterone acetate (a highly-
selective androgen synthesis inhibitor), (Draw 3) after three weeks,
and (Draw 4) after nine weeks of continuous abiraterone
treatment. The specific data for all profiled cells is presented in
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the supporting information. In addition, a similar sequencing
based method was used to obtain the CNV profile of one
metastatic site from the patient using a bone biopsy taken at the
time of diagnosis (5 months prior to draw 1) prior to receiving any
cancer-specific therapy. As shown in Figure 1A, and during the 7
month period between Draws 1 and 2, the patient exhibited initial
response to docetaxel-based chemotherapy followed by resistance.
Concurrently, the patient’s fluid biopsy showed a constant
proportion of AR+ and AR2 subpopulations while the overall
number of CTCs declined (Figure 1A, 1D, Figure S1 and Table
S1).
The genomic CNV profiles of CK+ cells from Draws 1 and 2
were of two types (Figures 2 and S2). Three of these cells were
negative for AR expression (CK+AR2) while the majority (16/19)
showed high levels of AR protein (CK+AR+). One AR2 and one
AR+ cell had near normal CNV profiles comparable to those
obtained from single CK2CD45+ leukocytes (Figure 2). All other
CK+AR+ cells exhibited a complex pattern of genomic rearrange-
ments that were similar to the genomic profile obtained
retrospectively from the patient’s bone metastasis (hormone naı¨ve
tissue sample) obtained at diagnosis (Figure 2 and Figure 3A). The
CK+AR+ cells and the bone metastasis sample shared multiple
gains and losses of chromosome arms plus a characteristic focal
amplification on 3p13 centered on the phosphatase regulatory
subunit PPP4R2 and containing at least two genes implicated in
cancer, FoxP1 [18,19] and MITF [20] (Figure 2). To the level of
resolution available, each of the shared events showed identical
genomic breakpoints, and in the hierarchical clustering analysis
the AR+ cells from draws 1 and 2 clustered together with the bone
metastasis (Cluster A in Figure 3A). From this evidence, we infer
that these cells are bona fide CTCs derived from the patient’s
metastatic lineage. Despite the clear lineage relationship, the AR+
circulating cells differed from the metastasis at the AR locus,
showing multicopy amplification of various segments on Xq12
containing the AR gene itself. AR amplification is frequent in
CRPC, and has been linked to progression from castration-
sensitive prostate cancer to CRPC [21]. It is noteworthy that each
of the AR amplifications (Figure 3C) are unique, arising from
multiple different breakpoints on either side of the AR gene,
indicating that AR amplification arose multiple independent times
(convergent evolution) likely as result of the selective pressure
imposed by the androgen deprivation therapy.
At Draw 3, after three weeks of abiraterone acetate treatment,
the patient displayed a clear clinical response as defined by
decrease in PSA and pain (Figure 1B). This response coincided
with an abrupt change in CTC phenotypes and genotypes.
Although the absolute number of CTCs in Draw 3 was
comparable to that of Draw 2, there was an almost complete
depletion of the AR+ CTC population (Figure 1A). The CK+ cells
identified in Draw 3 expressed little or no AR protein and also
differed morphologically, appearing to be significantly more
elongated than the AR+ cells from Draws 1 and 2 (Figure S1
and Table S1). This morphological change is reflected in a
decrease in the median cell roundness (Figure S3) from 0.87
(sd = 0.14) in Draw 1 and 2 to 0.62 (sd = 0.15) in Draw 3, p,10211
Wilcoxon rank-sum test (Figure 1C).
The apparent effect of treatment was also evident in the
genomic analysis of Draw 3 where the altered phenotypic states
correlated with distinct genomic profiles. The majority (10/12) of
phenotypically AR2 cells from Draw 3 were not amplified for AR
and exhibited apparently normal or near normal (pseudodiploid)
profiles (Figure S2) placing them in Cluster B in Figures 3A. One
of the two AR2 cells from this timepoint had the CNV signature
typical of Cluster A including amplification of AR, while the other
associated with a third cluster (Cluster C in Figure 3A), dominated
by cells from the subsequent timepoint (Draw 4). Missense
mutations affecting AR protein stability and/or nonsense muta-
tions in the AR gene could account for the AR phenotype-
genotype disparity in the last two cells. We interpret that the initial
response to abiraterone acetate significantly depleted the andro-
gen-dependent AR+ population, and that another AR2 population
dominated by pseudodiploid cells was present in the circulation.
Based on the total cell count, staying constant between draws 2
Figure 1. Abiraterone acetate induces phenotypic alterations
in the CTC population. (A) The total HD-CTCs counts, including the
number of phenotypically distinct AR+ and AR2 cells, was determined
for each blood Draw collected during therapeutic intervention. CTCs
were defined as AR positive if the AR signal intensity was higher than six
standard deviations over the mean (SDOM) of the surrounding
leukocytes (background). The bar-graph shows the change in the
distribution of the AR+ and AR2 CTC subpopulations along the course
of treatment, indicated in red and blue respectively, and the numbers
are presented above each bar. (B) PSA concentration measured at each
treatment timepoint. (C) Boxplot of cell roundness for each individual
CTC identified across the different treatment timepoints. (D) Represen-
tative 406 immunofluorescence images of AR+ and AR2 HD-CTCs from
the subpopulations identified in each treatment timepoint. Immuno-
fluorescence channels are colored as follows: nucleus: blue; cytokeratin:
red; AR: white; and CD45: green. AR phenotype is indicated in the
bottom left corner of each image. All graphs were constructed using
the ggplot2 and rgl packages in R.
doi:10.1371/journal.pone.0101777.g001
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and 3, we infer that the Draw 3 population is a consequence of
cancer, but from a source outside of the main tumor lineage
(Figure 3A).
Draw 4 was collected at the point of clinical progression, when
PSA levels increased after 9 weeks on abiraterone (Figure 1B). At
this point, the CTC count had decreased to 47% of the previous
timepoint, but had once again undergone a significant phenotypic
shift, as the majority of CTCs were once again AR+ with a cell
roundness value of 0.81 typical of cells from the first two draws
(Figure 1C and Figure S1). This finding, suggesting an association
between therapy response and a CTC phenotype rather than with
total CTC count, is consistent with a recently published study
where the expression of two markers for the AR signaling pathway
on CTCs was monitored in response to androgen-directed therapy
[22].
Alterations in response to therapy were again apparent at the
genomic level, as (6/10) cells formed the majority of a new,
apparently clonal, subpopulation (Cluster C in Figures 3A and
S2). The CNV signatures in Cluster C are clearly in the original
lineage, going back to the bone metastasis sampled before any
systemic therapy, but is now characterized by functionally relevant
events such as a narrow amplicon containing MYC, and the
disappearance of the FOXP1/MITF amplicon along with other
differences noted in Figures 2, 3A and 3B. MYC amplification is
one of the most common alterations observed in metastatic
tumors, and has been suggested to be a bypass mechanism for AR
independent resistance [23]. Interestingly a closer examination of
the genomic AR amplification (outlined in Figure 3C) shows that,
in contrast to the heterogeneous amplification boundaries
observed in earlier cells (cluster A), the cells in cluster C exhibit
a single profile shape with nearly uniform breakpoints and
significantly higher levels of AR amplification. Taken together
the genomic elements suggest that the Cluster C cells represent a
novel lineage, apparently resistant to abiraterone acetate, and
generated perhaps from a single resistant cell.
In addition, morphometric analysis of AR subcellular localiza-
tion showed that AR was generally localized in the nucleus of cells
from Draws 1 and 2, but was identified as significantly less
localized to the nucleus in the CTCs isolated in Draw 4 collected
at progression (p = 0.00017 Wilcoxon rank-sum test) (Figure 4).
This finding is particularly interesting in the light of recent studies
indicating that ligand independent AR splice variants may mediate
abiraterone resistance in a human CRPC xenograft model [24],
and that these truncated and constitutively active forms of AR is
found to be localized in the nucleus as well as cytoplasm in
prostate cancer cell lines [25].
Although our study is based on longitudinal study of a single
patient, our findings are consistent with previous studies involving
Figure 2. Concurrent phenotypic and genotypic profiling of single prostate tumor cells. Copy number variation profiles from the patient’s
bone metastasis; a control single WBC; and single CTCs from each of the four treatment timepoints are shown. The corresponding fluorescent image
of the cell used to generate the CNV profile is shown to the right. Relevant genomic alterations and their chromosome localizations occurring in each
specific draw are indicated with pale blue bars.
doi:10.1371/journal.pone.0101777.g002
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genomic analysis from either CTCs or circulating cell-free DNA
isolated from patients with metastatic prostate cancer [26,27].
However, these prior studies were generally limited to the
characterization of pooled samples from a single timepoint, and
therefore do not shed light into the temporal and dynamic
evolution of cancer under therapeutic selective pressure. Regard-
less, consistent with these prior reports we observed copy number
alterations in chromosome 8 (particularly gain in 8q and loss in
8p), which is one of the most frequent somatic mutations described
in prostate cancer [18]. In addition, our finding that AR
amplification was not found in sample obtained before initial
androgen-deprivation therapy, but occurred at high frequency in
later samples representing CRPC is consistent with multiple prior
studies linking AR amplification with androgen-independent
prostate cancer growth.
A Time Course of Tumor Evolution
Clonal evolution of cancer is a well-established principle that
has been validated in multiple published studies [28–30], as well
as, the appearance of somatic mutations in tumors in response to
therapeutic selective pressure [31,32]. We interpret the phenotypic
and genotypic changes in circulating cell populations presented
here as representing sequential steps of genetic evolution in
response to a multi-step therapeutic regime culminating in
treatment with abiraterone acetate.
The bulk metastatic biopsy taken prior to initiation of therapy
provides the root CNV profile to from which the subsequent time
course CTC profiles have evolved. It exhibits a backbone of CNV
elements that defines a lineage, based on CNV breakpoints, that is
carried forward in the circulating cells from blood draws taken
during later treatment. The first two of these draws were taken
after an initial course of androgen deprivation therapy (ADT)
(leuprolide acetate). One population in Draws 1 and 2 (Clone A)
was a clearly a direct descendant of the met biopsy profile with the
exception that all cells showed high-copy AR amplification and
strong AR protein expression. We interpret these cells to be the
products of metastatic deposits that had evolved to amplify the AR
gene locus and overexpress androgen receptor protein as a result
of genetic selection for resistance to the initial round of ADT. It is
noteworthy that in addition to the AR amplified cells, both draws
contained a significant fraction of cytokeratin positive, AR
negative cells with near-normal (pseudodiploid) genomes forming
a separate CNV cluster (Figure 3). It is also interesting that the
clonal structure of the AR+ cells changed very little between
Draws 1 and 2 despite intervening rounds of chemotherapy and
radiation therapy over a period of 7 months.
In contrast to the similarity of cell phenotype and genotype in
Draws 1 and 2, the selective effects of abiraterone acetate were
very evident in Draws 3 and 4. After three weeks of treatment the
androgen dependent, AR positive cells in Draws 1 and 2 were
Figure 3. Clonality and genomic aberrations in the CTC population. (A) Three different clonal lineages, represented as Cluster A, B and C,
were identified based on the comparison of 41 single cell CNV profiles in an unsupervised hierarchical clustering. The blood draw from which each
cell was isolated is indicated as Draw 1: yellow; Draw 2: orange; Draw 3: purple; and Draw 4: black. For reference, the bone metastasis FFPE tissue was
included in the tree, colored in green. Below the tree, a heatmap indicates the amplifications (red) and deletions (blue) across the entire genome of
each individual cell. (B) Frequency of genomic amplifications and deletions in the three clusters identified. Areas uniquely amplified (red) or deleted
(blue) in cluster A and C are highlighted. (C) A detail plot of the AR amplification event colored per draw for each individual cluster is shown.
doi:10.1371/journal.pone.0101777.g003
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nearly absent and the CK+ population consisted almost entirely of
AR negative pseudodiploid cells. The clone (Clone C) that would
become dominant at the nine-week timepoint (Draw 4) was first
seen as a single incidence in Draw 3. By Draw 4, AR+ cells had
once again become a substantial fraction of the population, albeit
with a significantly altered CNV profile (Figure 3). We thus infer
that Clone C was selected as a drug-resistant subclone from one of
the initially depleted metastatic sites. That the early and late stage
clones are clearly related and stem from the same lineage is evident
from the frequency graphs in Figure 3B, showing that most events
are maintained and have identical boundaries. Several other
events, however, are either new, deletions on 1q, 8q, and 15q and
gains of 3p, 15p, and complex rearrangement of 8q involving a
separate amplification of a narrow region containing MYC, or are
more frequent in the late stage cells. The co-occurrence of MYC
amplification along with re-emergence of AR protein expression
and AR amplification may have important therapeutic implica-
tions as c-Myc expression confers androgen-independent growth
[23]. While c-Myc has proved a difficult therapeutic target,
strategies which target key metabolic and other changes down-
stream of c-Myc activation are being investigated in many clinical
trials [33]. Our data suggests that co-targeting of c-Myc along with
AR may provide an approach to delay or prevent the emergence
of resistance to abiraterone acetate and other androgen-targeting
agents.
Through this selective process, the population of AR negative,
pseudodiploid cells remained a significant fraction of cytokeratin
positive cells. The presence of these phenotypically (Figure 1A)
and genotypically (Figure 3A) distinct cytokeratin positive cells
raises the question of their origin. Previous studies have
consistently identified cells in primary tumor tissue with similarly
unaltered or pseudodiploid CNV profiles [12]. We also cannot
exclude that they represent a pre-existing minor population of
normal epithelial cells exposed by depletion of the cancer cells in
Draw 3, however, that the number of these cells in Draw 3 was
comparable to the numbers in Draws 2 and 4 would make that less
likely. Alternatively, they may represent tumor associated macro-
phage lineage cells with phagocytosed intracytoplasmic cytokeratin
sloughed off from tumor sites as they are depleted of sensitive cells
or a castration resistant stem-like tumor cell population recently
described in engrafted prostate tumors and phenotypically
characterized as CK+ AR2 cells [34]. However, further interro-
gation of single point mutations combined with protein expression
analysis will be required to gain insight into the nature of these
cells and their role in tumor progression, if any.
In an era of clinical oncology that is progressively moving
towards targeted cancer therapy, approaches that allow for non-
invasive monitoring of therapeutic response at both phenotypic
and genetic levels are essential. We have chosen to approach this
goal through a combined phenotypic and genetic analysis of non-
leukocyte circulating nucleated cells, without a pre-selection step
that may bias the CTC population. Our method allows us to
correlate genomic events with complex phenotypes based on
protein expression and cell morphology. Alternative methods, such
as sequencing of free DNA from plasma (ctDNA) are also powerful
tools and can yield both mutation and copy number information,
but only for an admixture of the various cellular components [35].
In this case study, we show the remarkable extent and speed of the
Figure 4. AR subcellular localization changes at the time of disease progression. (A) Comparison of the AR subcellular localization in the
CTCs identified in the blood prior to and after nine weeks of abiraterone treatment. Correlation between the AR and DAPI signals within the cell is
indicative of AR being colocalized with DAPI, i.e. localized in the cell nucleus. High correlation was generally seen before abiraterone treatment, but a
shift to less nuclear stain was observed after nine weeks of treatment (p = 0.00017, Wilcoxon sum-rank test). (B) and (D) Height maps constructed
from the pixel intensities of CK (red), AR (green) and DAPI (blue) in representative CTCs to visualize the subcellular localization of AR. The cell in (B)
was isolated before abiraterone initiation and displays AR staining confined to the nucleus, while cytoplasmic AR staining is observed in the CTC
identified at the time of therapeutic relapse (D). (C) and (E) Plots of AR versus DAPI signal intensities for each pixel inside the cell in the 406 images of
the CTCs in (B) and (D), respectively. Each plot point is colored by the corresponding CK signal intensity. Nuclear localization was observed as positive
correlation between the two intensities (C), and nuclear exclusion as negative correlation (E). All graphs and were done using the ggplot2 and rgl
packages in R.
doi:10.1371/journal.pone.0101777.g004
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genomic reorganization as putative-resistant clones emerge at the
time of treatment failure. Although, we cannot establish a
mechanistic relationship between the large CNV changes and
the eventual resistance to abiraterone acetate based on a single
patient, it appeared that after 9 weeks of targeted therapy the
original CTC population was not completely eliminated and an
apparently drug-resistant clone was present. Finally, the integra-
tion of data across multiple subjects will open the door for a deeper
understanding of the mechanisms and timing of resistance and
allow for rationally-designed, personalized treatments based on
sequential, combined, or intermittent application of therapeutic
agents.
Supporting Information
Figure S1 Representative gallery of 406high resolution
immunofluorescence images of the two phenotypically
distinct CTCs subpopulations identified. A and B,
Composite and non-merged images of an AR+ and AR2 HD-
CTC isolated from pre docetaxel (A) and pre abiraterone (B)
treatment timepoints. C and D, Two different AR2 and AR+
HD-CTCs, the predominant tumor cell phenotypes found in 3 (C)
and 9 weeks post abiraterone (D). Panel D, CTCs with different
pattern of AR subcellular localization. Nuclear and cytoplasmic
AR is shown in the top panel and nuclear AR in the bottom panel.
Composite and non-merged images for the individual immuno-
fluorescence channels were colored as followed: DAPI (blue);
cytokeratin-CK (red), androgen receptor-AR (white) and CD45
(green).
(DOCX)
Figure S2 Complete collection of single CTC CNV
profiles. The genome wide copy number fingerprints for all
successfully profiled cells at each of different treatment timepoint.
(DOCX)
Figure S3 Examples of cell roundness estimation. The
cell shape was analyzed by tracing the cell cytoplasm contour in
the composite image of each CTC. The traced cell image was
imported into R, and an ellipsis was fitted to the shape using a least
squares fitting algorithm described by Halir and Flusser. Black line
represents the manually drawn cell outline, red line the fitted
ellipse. The cell roundness is estimated as the fraction of the de
facto cell area and the area of a circle with the radius set to the
cell’s major axis. The cell roundness calculated to be 0.62 for the
oval-shaped cell (left) and 0.96 for the more rounded cell (right).
The p-value used in the comparison of the roundness between the
CTCs isolated between the different draws was calculated using
the Wilcoxon rank-sum test.
(DOCX)
Table S1 Summary of the different phenotypic and
genotypic traits analyzed in the 41 individual cells
profiled for copy number alterations. Concordance be-
tween AR phenotype-genotype was determined by comparison of
the AR amplification status with the AR staining phenotype
(Negative or Positive) for each individual cell. In red are cells that
exhibited discordant AR phenotype-genotype.
(DOCX)
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